2021
The effect of live attenuated influenza vaccine on pneumococcal colonisation densities among children aged 24–59 months in The Gambia: a phase 4, open label, randomised, controlled trial
Peno C, Armitage E, Clerc M, Balcazar Lopez C, Jagne Y, Drammeh S, Jarju S, Sallah H, Senghore E, Lindsey B, Camara J, Bah S, Mohammed N, Dockrell D, Kampmann B, Clarke E, Bogaert D, de Silva T. The effect of live attenuated influenza vaccine on pneumococcal colonisation densities among children aged 24–59 months in The Gambia: a phase 4, open label, randomised, controlled trial. The Lancet Microbe 2021, 2: e656-e665. PMID: 34881370, PMCID: PMC8632704, DOI: 10.1016/s2666-5247(21)00179-8.Peer-Reviewed Original ResearchMeSH KeywordsChildCoinfectionGambiaHumansInfluenza VaccinesInfluenza, HumanPneumococcal VaccinesStreptococcus pneumoniaeVaccines, AttenuatedConceptsPneumococcal densityRespiratory viral infectionsLAIV groupMiddle-income country populationsPneumococcal carriageRespiratory virusesControl groupDay 7Influenza vaccineViral infectionDay 21Asymptomatic respiratory viral infectionsHigher pneumococcal carriage ratesHigh pneumococcal carriageInfluenza vaccine programsNasopharyngeal pneumococcal carriagePneumococcal carriage rateUse of LAIVAttenuated influenza vaccineUpper respiratory tractInvestigator teamOpen labelRandomisation sequencePrimary outcomeCarriage prevalence
2019
Early Signals of Vaccine-driven Perturbation Seen in Pneumococcal Carriage Population Genomic Data
Chaguza C, Heinsbroek E, Gladstone RA, Tafatatha T, Alaerts M, Peno C, Cornick JE, Musicha P, Bar-Zeev N, Kamng’ona A, Kadioglu A, McGee L, Hanage WP, Breiman RF, Heyderman RS, French N, Everett DB, Bentley SD. Early Signals of Vaccine-driven Perturbation Seen in Pneumococcal Carriage Population Genomic Data. Clinical Infectious Diseases 2019, 70: 1294-1303. PMID: 31094423, PMCID: PMC7768739, DOI: 10.1093/cid/ciz404.Peer-Reviewed Original ResearchMeSH KeywordsCarrier StateChildHumansInfantMalawiMetagenomicsNasopharynxPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugateConceptsYears of ageVaccine serotypesWhole-genome sequencingHigh disease burdenAntibiotic resistanceLow-income settingsPCV introductionReplacement serotypesVT serotypesPneumococcal diseaseNonvaccine serotypesCarriage rateDisease burdenPneumococcal isolatesSerotype dynamicsContinued surveillancePCV effectsAge groupsSerotypesSerotype diversityAgeVaccineResistant lineagesPCVChildren
2017
Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi
Chaguza C, Cornick JE, Andam CP, Gladstone RA, Alaerts M, Musicha P, Peno C, Bar-Zeev N, Kamng'ona AW, Kiran AM, Msefula CL, McGee L, Breiman RF, Kadioglu A, French N, Heyderman RS, Hanage WP, Bentley SD, Everett DB. Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi. Vaccine 2017, 35: 4594-4602. PMID: 28711389, PMCID: PMC5571440, DOI: 10.1016/j.vaccine.2017.07.009.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBacterial CapsulesChildChild, PreschoolDrug Resistance, Multiple, BacterialEvolution, MolecularFemaleGenome, BacterialHigh-Throughput Nucleotide SequencingHumansInfantInfant, NewbornMalawiMalePneumococcal InfectionsPneumococcal VaccinesPrevalenceRetrospective StudiesSerogroupSerotypingStreptococcus pneumoniaeVaccinationVaccines, ConjugateYoung AdultConceptsPneumococcal conjugate vaccineMDR ratePneumococcal isolatesHigher MDR rateImplementation of PCV13Prevalence of serotypesNon-vaccine serotypesInvasive pneumococcal isolatesGood infection preventionAntibiotic resistance ratesAntibiotic resistanceAbsence of vaccinesReplacement serotypesSerotype replacementInvasive pneumococciPneumococcal infectionConjugate vaccineSerotype 12FDisease burdenInfection preventionSerotype prevalenceHigh prevalenceInvasive isolatesContinued surveillanceResistance rates